Using an early patient experience as a launching point, Miguel Regueiro, MD, reflects on the gradual shift away from treatments for ulcerative colitis, such as the long-term prescribing of steroids and surgery — both effective but with undesirable side effects — to newer therapies that are more precise in their agency, such as monoclonal antibodies and small molecules.
The resulting benefits to patients, when coupled with a determined integration of social and psychological factors, amount to a practical revolution in ulcerative colitis care over the past three decades.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Ulcerative Colitis: Maximizing the Benefit to Patients - Medscape - May 16, 2022.